Stockscreener 앱 받기
1.62
3.85%
0.06
시간 외 거래:
1.61
-0.01
-0.62%
전일 마감가:
$1.56
열려 있는:
$1.55
하루 거래량:
1.45M
Relative Volume:
0.55
시가총액:
$686.36M
수익:
$49.80M
순이익/손실:
$-50.34M
주가수익비율:
-11.67
EPS:
-0.1388
순현금흐름:
$-67.85M
1주 성능:
-5.81%
1개월 성능:
+6.58%
6개월 성능:
+36.13%
1년 성능:
+353.15%
1일 변동 폭
$1.54
$1.64
1주일 범위
$1.54
$1.79
52주 변동 폭
$0.32
$1.83
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.62 | 660.94M | 49.80M | -50.34M | -67.85M | -0.1388 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-05 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | 개시 | H.C. Wainwright | Buy |
| 2024-04-30 | 개시 | Leerink Partners | Outperform |
| 2023-03-07 | 개시 | Jefferies | Hold |
| 2022-08-12 | 개시 | Piper Sandler | Overweight |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
| 2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
| 2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2018-07-31 | 재확인 | Stifel | Buy |
| 2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-03-01 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-01 | 재확인 | Wedbush | Outperform |
| 2016-10-07 | 개시 | H.C. Wainwright | Buy |
| 2016-08-05 | 재확인 | Wedbush | Outperform |
| 2016-08-02 | 개시 | Citigroup | Buy |
| 2016-03-02 | 재확인 | Wedbush | Outperform |
| 2015-11-09 | 재확인 | Wedbush | Outperform |
| 2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
| 2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
| 2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
Lexicon Pharmaceuticals advances chronic pain treatment options with focus on non opioid innovation - Traders Union
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2025 Earnings Call Transcript - MSN
Lexicon Pharma spikes after insider buy - MSN
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Growth Value: How does Lexicon Pharmaceuticals Inc compare to its peers2026 EndofMonth & Low Drawdown Investment Ideas - baoquankhu1.vn
Dip Buying: How much upside does Lexicon Pharmaceuticals Inc have2026 PreEarnings & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
HC Wainwright raises its price target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and maintains a buy rating - MSN
Lexicon Pharmaceuticals, Inc.Common Stock (NQ: LXRX - The Chronicle-Journal
Lexicon Pharmaceuticals (LXRX) 2025 10-K: pipeline updates, collaborations - Stock Titan
Lexicon Pharmaceuticals (NASDAQ: LXRX) asks holders to double shares, renew equity plans - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK) - The Globe and Mail
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 earnings call transcript - MSN
H.C. Wainwright reiterates Buy on Lexicon Pharmaceuticals stock By Investing.com - Investing.com Canada
H.C. Wainwright Raises its Price Target on Lexicon Pharmaceuticals, Inc. (LXRX) to $6 from $4 and Maintains a Buy Rating - Insider Monkey
Lexicon Pharmaceuticals at Leerink Conference: Strategic Pipeline Focus By Investing.com - Investing.com Canada
LXRX: Late-stage trials and regulatory milestones drive pipeline progress and strategic partnerships - TradingView
Lexicon Pharmaceuticals (LXRX) to Present Key Findings on Sotagl - GuruFocus
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes - The Manila Times
Diabetes drug sotagliflozin cut low-sugar events, across kidney stages - Stock Titan
Citigroup Raises Price Target for Lexicon Pharmaceuticals (LXRX) - GuruFocus
Citigroup Forecasts Strong Price Appreciation for Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock - MarketBeat
Lexicon Pharmaceuticals Signals Leaner Path to Key Milestones - TipRanks
What is HC Wainwright's Estimate for LXRX Q1 Earnings? - MarketBeat
Quarterly Risk: How does Lexicon Pharmaceuticals Inc compare to its peersQuarterly Earnings Summary & Daily Entry Point Trade Alerts - baoquankhu1.vn
Lexicon Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:LXRX) 2026-03-08 - Seeking Alpha
Volume Summary: Does Lexicon Pharmaceuticals Inc meet Warren Buffetts criteria2025 Retail Activity & Weekly High Return Forecasts - baoquankhu1.vn
Structure Therapeutics Stock Surges 200% This Past Year as One Fund Cuts Stake by $15.5 Million - AOL.com
Lexicon Pharmaceuticals prices $94.6M share offering - MSN
Lexicon Pharmaceuticals Q4 2025 earnings preview - MSN
Lexicon Pharmaceuticals 2025 Financial Report: Q4 Loss Narrows, Beats EstimatesNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 5.8% Following Earnings Beat - MarketBeat
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q4 2025 Earnings Call Transcript - Insider Monkey
FY2027 Earnings Forecast for LXRX Issued By HC Wainwright - MarketBeat
H.C. Wainwright Maintains Buy on LXRX Lexicon Pharmaceuticals Mar 2026 - Meyka
Lexicon outlines 2026 milestones as SONATA-HCM enrollment surpasses 50% and cash position is strengthened - MSN
HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment - AOL.com
Lexicon Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Lexicon Pharmaceuticals 2025 10-K: $49.8M Revenue, $0.14 EPS Loss - TradingView
Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates - Bitget
Lexicon Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Gap DownShould You Sell? - MarketBeat
Lexicon Pharmaceuticals stock price target raised to $6 by H.C. Wainwright - Investing.com Canada
Lexicon Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Lexicon Pharmaceuticals (NASDAQ:LXRX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Lexicon Pharmaceuticals (LXRX) Target Price Raised by HC Wainwri - GuruFocus
Lexicon Pharmaceuticals (NASDAQ:LXRX) Releases Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Lexicon (LXRX) Q4 2025 Earnings Call Transcript - The Globe and Mail
Lexicon: Q4 Financial Results Overview - Bitget
Earnings call transcript: Lexicon Pharmaceuticals beats Q4 2025 expectations - Investing.com
Earnings call transcript: Lexicon Pharmaceuticals beats Q4 2025 expectations By Investing.com - Investing.com Nigeria
Lexicon: Q4 Earnings Snapshot - kare11.com
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):